The vaccine contains capsular polysaccharide conjugates for 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F and 33F) that cause invasive pneumococcal disease.
Researchers report findings from SAATELLITE, a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial that assessed the safety and efficacy of suvratoxumab for Staphylococcus aureus pneumonia.
Previously, the initial loading dose of Nuzyra for CABP was administered only by IV infusion.
Nucleic acid-based viral diagnostics are suggested for hospitalized patients with suspected community-acquired pneumonia.
Positive topline results were announced from two phase 3 studies evaluating V114, an investigational 15-valent pneumococcal conjugate vaccine, in pediatric patients for the prevention of invasive pneumococcal disease.